Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | CCNC | P24863 | 1/20 | 0.39 |
| ▸ | CDK8 | P49336 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7673879 | 0.87 | DRD2 (0.53) | DRD2CYP11B1CYP11B2CTSLCTSS | |
| SCHEMBL7677565 | 0.87 | CYP1A2 (0.48) | DRD2CYP11B1CYP11B2HDAC1HDAC6 | |
| SCHEMBL12598196 | 0.83 | MTNR1A (0.53) | DRD2CTSLCTSSCTSKHDAC1 | |
| SCHEMBL31129885 | 0.82 | CYP11B1 (0.47) | DRD2CYP11B1CYP11B2 | |
| SCHEMBL5212016 | 0.81 | DRD2 (0.47) | DRD2CYP11B1CYP11B2BRD4 | |
| SCHEMBL7677157 | 0.81 | HDAC1 (0.43) | CTSLCTSSCTSKHDAC1HDAC6 | |
| SCHEMBL7677151 | 0.81 | HDAC1 (0.43) | CTSLCTSSCTSKHDAC1HDAC6 | |
| SCHEMBL5212333 | 0.78 | DRD2 (0.49) | DRD2BRD4 | |
| SCHEMBL8082130 | 0.77 | DRD2 (0.42) | DRD2CYP11B1CYP11B2CCNCCDK8 | |
| SCHEMBL10564578 | 0.76 | CYP3A4 (0.57) | CTSLCTSSCTSKHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112148-A1 | INDOLINE COMPOUNDS | FERRER INTERNACIONAL S.A. | 2011-05-12 | — | — | US | disclosed |
| WO-2009053440-A1 | INDOLINE COMPOUNDS | FERRER INTERNACIONAL S.A. (ES) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112148-A1 | INDOLINE COMPOUNDS | MTNR1A, MTNR1B, TPH2 | DRD2 98/4885CYP11B1 39/4885CYP11B2 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.